Novel bioartificial liver support system: preclinical evaluation

Area of Science:

• Hepatology
• Biomedical Engineering
• Preclinical Research

Background:

• Acute liver failure (ALF) presents a critical unmet medical need.
• Current treatments for ALF are limited, necessitating innovative therapeutic strategies.
• Bioartificial liver support systems (BLSS) offer a potential solution by bridging patients to liver transplantation or recovery.

Purpose of the Study:

• To evaluate the preclinical safety and efficacy of a novel bioartificial liver support system (BLSS).
• To assess the impact of BLSS treatment timing on survival in a canine model of D-galactosamine-induced liver failure.

Main Methods:

• A D-galactosamine canine liver failure model was established.
• Porcine hepatocytes were cultured within a hollow fiber cartridge, forming the BLSS.
• Canine subjects received D-galactosamine and were divided into control and BLSS treatment groups with varying treatment initiation times.
• Physiological parameters, including blood pressure, intracranial pressure, and liver enzymes, were continuously monitored.

Main Results:

• All animals developed severe liver failure, characterized by hemodynamic instability, elevated intracranial pressure, hepatocellular damage, and metabolic acidosis.
• BLSS treatment, initiated at 16-18 hours or 24-26 hours post-D-galactosamine administration, significantly prolonged survival compared to the control group (p=0.047).
• No significant difference in survival was observed between the two BLSS treatment initiation times (p=0.694).

Conclusions:

• The novel bioartificial liver support system (BLSS) demonstrates significant efficacy in prolonging survival in a preclinical canine model of acute liver failure.
• The findings support the readiness of this BLSS for Phase I clinical safety evaluation.
• This BLSS holds promise as a therapeutic option for patients suffering from acute liver failure.